280 related articles for article (PubMed ID: 25096059)
21. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
[TBL] [Abstract][Full Text] [Related]
22. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (
Matsumoto T; Okabe H; Yamashita YI; Yusa T; Itoyama R; Nakao Y; Yamao T; Umzaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Nitta H; Hayashi H; Imai K; Chikamoto A; Baba H
Surg Today; 2019 Jan; 49(1):21-26. PubMed ID: 30128759
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
26. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors.
Partelli S; Rinzivillo M; Maurizi A; Panzuto F; Salgarello M; Polenta V; Delle Fave G; Falconi M
Neuroendocrinology; 2014; 100(4):293-9. PubMed ID: 25301162
[TBL] [Abstract][Full Text] [Related]
27. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
28. (18)F-FDG-PET/CT findings in pancreatic metastasis.
Hu S; Zhang J; Zuo C; Cheng C; Liu Q; Sun G
Radiol Med; 2015 Oct; 120(10):887-98. PubMed ID: 25795439
[TBL] [Abstract][Full Text] [Related]
29. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
[TBL] [Abstract][Full Text] [Related]
30. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
[TBL] [Abstract][Full Text] [Related]
31. Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT.
Toshikuni N; Kai K; Fujisawa M
Ann Nucl Med; 2008 Feb; 22(2):133-7. PubMed ID: 18311538
[TBL] [Abstract][Full Text] [Related]
32. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of a deep-inspiration breath-hold 18F-FDG PET/CT technique in diagnosing liver, bile duct, and pancreas tumors.
Nagamachi S; Wakamatsu H; Kiyohara S; Fujita S; Futami S; Arita H; Nishii R; Tamura S; Kawai K
Nucl Med Commun; 2009 May; 30(5):326-32. PubMed ID: 19282791
[TBL] [Abstract][Full Text] [Related]
34. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
Segard T; Robins PD; Yusoff IF; Ee H; Morandeau L; Campbell EM; Francis RJ
Clin Nucl Med; 2013 Jan; 38(1):1-6. PubMed ID: 23242037
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of
Sato A; Masui T; Yogo A; Uchida Y; Nakano K; Anazawa T; Nagai K; Takaori K; Nakamoto Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2020 Jul; 27(7):414-420. PubMed ID: 32196985
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET/CT features of pulmonary sclerosing hemangioma.
Lee E; Park CM; Kang KW; Goo JM; Kim MA; Paeng JC; Lee HJ; Park HS; Chung DH
Acta Radiol; 2013 Feb; 54(1):24-9. PubMed ID: 22291338
[TBL] [Abstract][Full Text] [Related]
37. Clinical Usefulness of
Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
[TBL] [Abstract][Full Text] [Related]
38. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
[TBL] [Abstract][Full Text] [Related]
39. 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.
Bucau M; Laurent-Bellue A; Poté N; Hentic O; Cros J; Mikail N; Rebours V; Ruszniewski P; Lebtahi R; Couvelard A
Neuroendocrinology; 2018; 106(3):274-282. PubMed ID: 28803235
[TBL] [Abstract][Full Text] [Related]
40. The role of 18F-FDG PET-CT in the detection of unknown primary malignancy: a retrospective study.
Yaylali O; Kiraç FS; Yüksel D
Turk J Med Sci; 2016 Feb; 46(2):474-82. PubMed ID: 27511514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
